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Abstract
Objective—We aimed to measure separately the contributions of heat and humidity to changes in 
levels of hemoglobins A and S in dried-blood-spot (DBS) samples.
Design and methods—We stored paired sets of DBSs at 37 °C for predetermined intervals in 
low-humidity and high-humidity environments. Hemoglobin A and S levels of all samples in each 
complete set were measured in a single high performance liquid chromatography run.
Results—During the one-month storage intervals, both hemoglobin species lost about 35% of 
initial levels in low-humidity storage and almost all of initial levels in high-humidity storage.
Conclusions—Minimizing both humidity and temperature in the transportation and storage 
environments of DBS samples is essential to maintaining the integrity of the hemoglobin tetramer 
molecules.
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1. Introduction
Sickle cell diseases are inborn blood disorders caused by the presence of an abnormal form 
of hemoglobin, hemoglobin S (HbS). Molecules of both HbS and normal adult hemoglobin 
(HbA) consist of two α polypeptide chains and two β polypeptide chains. The α chains of 
the two hemoglobins are identical, but the glutamic acid that is the 6th amino acid residue 
from the N-terminus of the HbA β chain is replaced by a valine residue in HbS. This small 
difference in the molecular composition of HbS causes clinically significant sickle cell 
diseases in persons who: 1) are homozygous for HbS, 2) are heterozygous for HbS and one 
of several other abnormal hemoglobins; or 3) are carriers of both the HbS mutation and 
mutations that cause thalassemias (decreased globin chain production which leads to 
decreased HbA production). Sickle cell diseases cause anemia, acute pain episodes, and in 
some cases, death during the early years of life. Data from a number of state wide newborn 
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screening programs show that mortality from sickle cell disease during the first 3 to 4 years 
of life is virtually eliminated by universal screening and appropriate follow-up and treatment 
[1]. Three sickle cell diseases (sickle cell anemia, sickle hemoglobin C disease, and sickle β 
thalassemia) are included in the United States' recommended uniform screening panel [2]. 
Newborn screening for these disorders is universal in the United States where newborn 
screening samples are collected on filter paper, dried, and transported at ambient 
temperatures and humidities to state, regional, or state-associated contract laboratories for 
analysis. Little information about the stabilities of HbS (the marker of sickle cell diseases) or 
HbA in dried-blood spot (DBS) samples during transport and storage is available. 
Understanding and controlling for environmental variables are critical in sustaining effective 
operations of newborn screening and associated quality assurance programs that store and 
transport DBS samples in a wide range of environments.
In 2011, we performed accelerated degradation studies of 34 disorder markers as part of 
routine evaluations of DBS materials prepared by the Newborn Screening Quality Assurance 
Program of the Centers for Disease Control and Prevention (CDC) to assist laboratories with 
monitoring the performance of their newborn screening tests [3].We examined the stabilities 
of those markers in a single normalized study design that included temperature and humidity 
variables [4].We were unable to include HbS (the marker for the three recommended sickle 
cell diseases) or HbA in our 2011 studies because of methodological limitations. A recently 
acquired high performance liquid chromatography (HPLC) system has enabled us to 
measure levels of hemoglobin species and examine their stabilities in DBSs stored under 
various environmental conditions. We initiated accelerated degradation studies to compare 
the stabilities of HbS and HbA in DBSs stored at an elevated temperature (37 °C) and at low 
(below 30%) or high (above 50%) relative humidity for predetermined intervals. The 
objectives of the studies were to measure separately the contributions of heat and humidity 
to the degradation of HbS and HbA in DBS samples.
2. Materials and methods
2.1. Preparation of DBS materials
The DBS materials for these studies were made from blood collected in EDTA from a single 
anonymous adult HbS carrier (HbS carriers have one gene carrying the HbS mutation and 
one gene without the mutation.). The whole blood was adjusted to 50 ± 1% hematocrit by 
plasma removal to simulate the hematocrit of newborns and dispensed in 75 μL aliquots 
onto horizontally suspended sheets of Ahlstrom 226 (www.perkinelmer.com) filter paper. 
The blood spots were dried overnight under ambient conditions before 6 representative 
sheets, taken from throughout the production batch, were removed for the characterization 
of initial HbS and HbA levels and the evaluation of the production batch homogeneity. All 
other sheets of DBSs were separated by sheets of weighing paper (www.fishersci.com) and 
placed in Bitran Series S liquid-tight zip-closure specimen bags (com-pac.com)with 
desiccant packets (polylam.com) and 30–50% humidity indicator cards 
(www.desiccare.com) to ensure that storage humidity was maintained below 30%. The 
sealed bags of DBS materials were stored at −70 °C until use (results from stability studies 
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of lysosomal enzymes have shown that proteins in dried-blood spots stored at −70 °C are 
stable for more than a year [5]).
2.2. Characterization of initial marker levels and validation of homogeneity of the DBS 
production lot
We performed duplicate analyses of the first, 21st, 41st, 61st, 81st, and last sheets of the 
prepared DBS materials on each of five days. We used the acquired data to measure initial 
marker levels in the DBSs and to estimate the variability of the analyses. We used 
previously described statistical procedures [6] to evaluate the homogeneity of the production 
batch. In brief, we calculated a best-fit line from the average marker level of each card 
plotted against the card number. We calculated the batch deviation by multiplying the best-
fit line slope by the number of cards in the production batch, and we calculated the residual 
deviation of the batch by taking the square root of the average of the variation of each of the 
6 cards tested. We considered the marker level to be homogenous throughout the batch if the 
absolute value of the batch deviation was smaller than the residual deviation.
2.3. Accelerated degradation study design
We performed accelerated degradation studies of hemoglobins A and S according to the 
normalized study design we used to examine stabilities of 34 other disorder markers [4]. In 
accordance with that design, we stored eleven-member paired sets of the DBS materials at 
37 °C in Bitran Series S zip-closure specimen bags containing humidity indicator cards that 
indicated by color change humidities below 30% (blue) and above 50% (pink). One set of 
the pair was stored with relative humidity controlled below 30% by enclosing desiccant 
packets with the DBSs and zip-sealing the bags before storage. The other set was stored 
without desiccant in open Bitran bags in a high-humidity chamber which was monitored by 
periodic hygrometer readings to maintain humidity above 90%. The Day 0 member of each 
sample set (in a zip-closure bag with humidity maintained below 30%) remained in −70 °C 
storage throughout the study to serve as the storage stability control for its sample set. At 
predetermined intervals throughout the 31-to-32 day accelerated degradation studies, we 
removed DBSs from each sample set from 37 °C storage and transferred them to optimal 
storage at −70 °C. Immediately before transfer, we added desiccant packets to the bags 
containing DBSs that had been stored at high humidity and zip-sealed those bags to ensure 
that they were stored at optimal humidity. We measured the marker levels of all samples in 
each complete sample set in triplicate in a single analytic run.
2.4. HPLC analysis method
We used a Trinity Biotech Genesys Ultra2 Variant HPLC system (www.trinitybiotech.com) 
to quantitate, in each high-resolution chromatogram, the peak areas of HbS and HbA and the 
total area of all peaks. We also purchased the expendable supplies for the hemoglobin 
variant assay (reagents, hemoglobin reference material and controls, GeneSys™ variant ion 
exchange column, vials, filter frits, and microplate sealing film) from Trinity Biotech.
In this analytic system, the percentage of the total peak area attributable to each marker is 
used to express the marker concentrations. We used these percentages to express initial 
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levels of HbS and HbA in the DBS materials and to monitor the degradation of the 
hemoglobin molecules during the accelerated degradation studies.
2.5. Analysis of accelerated degradation studies data
We used geometric means of triplicate measurements of initial (Day 0) marker levels and 
marker levels remaining on the last day of each degradation study to determine the 
percentage of each marker's initial level that was lost during the study. We attributed marker 
losses from samples stored at low humidity to the effects of the elevated storage 
temperature. We subtracted the percentage loss of each marker from the sample set stored at 
low humidity from the percentage loss sustained by the paired sample set stored at high 
humidity and attributed the difference to the effects of elevated storage humidity.
3. Results
3.1. DSB characterization results
Average initial hemoglobin levels, obtained from HPLC analysis and expressed as the ratio 
of hemoglobin-marker peak area to total peak area × 100%, were: HbA―51.3% ± 0.9% and 
HbS―31.6% ± 1.9% (Table 1). The DBS characterization data, analyzed by our routinely 
used homogeneity evaluation protocol [6], showed that the DBS production lot met the 
criterion for acceptable homogeneity (Table 1).
3.2. Accelerated degradation results
The degradations of HbA and HbS molecules after each storage interval are shown as the 
remaining percentages of initial (Day 0) hemoglobin levels (Fig. 1). Results from the 
comparison of intact hemoglobin tetramer levels on the initial and final days of the 37 °C 
accelerated degradation study indicate that HbA and HbS levels in DBSs stored at low 
humidity experienced about 35% loss during a 32-day storage period. In DBSs stored at high 
humidity, both HbA and HbS lost more than 99% of their initial levels during a 31-day 
storage period. We subtracted the degradation that occurred during low humidity storage 
(and was attributed to effects of the elevated storage temperature) from the almost 100% 
degradation that occurred during high humidity storage to find that about 65% of the 
degradation was attributable to the effects of high storage humidity (Table 2).
4. Discussion
The standardized protocol used to characterize the initial marker levels and the homogeneity 
of marker distribution in the DBS material production batch is used routinely by the 
Newborn Screening Quality Assurance Program to validate its proficiency testing 
specimens. The initial levels of HbA (51.3%) and HbS (31.6%) in the DBS materials 
prepared for our stability studies are typical of circulating levels of the two hemoglobin 
species in HbS carriers [7, 8].
The accelerated degradation studies were carried out at 37 °C at low and high relative 
humidities for 31 to 32 days for study convenience (elevated storage temperature [9, 10] or 
elevated humidity [11, 12] accelerates the degradation process, thus enabling the 
measurement of changes in marker levels in a short study period.) Additionally, the study 
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conditions mimic those encountered during some transportation environments, such as 
summer transit in hot courier trucks, in which DBSs may be exposed to elevated 
temperatures before arrival at testing laboratories.
The goal of these studies was to measure the separate contributions of elevated temperature 
and elevated humidity exposure to changes in levels of HbS, the marker for sickle cell 
diseases, and in levels of the normal adult hemoglobin, HbA.
HPLC results from our accelerated degradation studies showed that degradation curves of 
HbS and Hb A were similar and that both hemoglobins were highly susceptible to the 
adverse effects of high humidity in the DBS storage environment. Comparison of 
hemoglobin levels on the initial and final days of the 37 °C accelerated degradation studies 
indicates that most of their degradation was attributable to the adverse effects of high 
humidity. Both HbA and HbS lost more than 99% of their initial levels before the end of the 
month-long high-humidity degradation study (Table 2), and both hemoglobins lost more 
than half of their initial levels within the first 10 days of high-humidity storage (Fig. 1).
Understanding susceptibilities of markers in DBS samples to heat-related and moisture-
related degradation is important for maintaining sample integrity for high-quality 
measurements. We have shown that minimizing both humidity and temperature of the DBS 
transport and storage environment is essential for ensuring the integrity of hemoglobin 
molecules especially when transportation time exceeds a few days. The DBS samples from 
CDC's Newborn Screening Quality Assurance Program are transported worldwide in closed 
containers with desiccant to assure that high-quality DBSs arrive for the assessment of 
laboratory performance.
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Recoveries of hemoglobins A and S from dried-blood spots stored for pre-determined 
intervals at 37 °C in low-humidity and high-humidity environments.
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Table 1
Characterization of hemoglobin A (Hb A) and hemoglobin S(Hb S) levels in dried-blood-spot materials used 
for accelerated degradation studies.
Method High performance liquid chromatography
Hemoglobin Hb A Hb S
Averagea 51.27% 31.58%
Standard deviation 0.87 1.90
Coefficient of variation 1.69% 6.00%
Slopeb −0.004 −0.003
Batch deviationc −0.357 −0.299
Residual deviationd 0.868 1.975
Homogenouse Yes Yes
a
Expressed as the percentage of total peak area attributable to each marker.
b
Best fit line slope from the average marker level of each card versus card number.
c
Batch deviation = slope × number of cards in the batch.
d
Residual deviation = square root of the average of the variation of each card.
e
Homogenous if absolute value of batch deviation is smaller than residual deviation.
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Table 2













(days) (%)c (%) (%)d
A 31 + 1 >99 36 64
S 31 + 1 >99 33 67
a
Percentages shown were derived from geometric means of triplicate determinations.
b
Low relative humidity < 30%; high relative humidity > 50%.
c
Approximate loss. Amount remaining was less than 1% of total peak area of the HPLC chromatogram.
d
Derived by subtracting loss during storage at low humidity from loss during storage at high humidity.
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